• Home
  • Category: Medical Oncology

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Epithelioid sarcoma is a rare and aggressive soft-tissue sarcomo subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependen...

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. At 24 months, progression-free survival was 77% in patien...

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Gemogenovatucel-T is an autologous tumour cell vaccine manufactured from harvested tumour tissue. It reduces expression of furin and downstream TGF-β1...

Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial

Survival outcomes for patients with recurrent or advanced cervical cancer are poor. GX-188E vaccination has been shown to induce human papillomavirus...

Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial

Long-term follow-up results for the Costa Rica Vaccine Trial. Women aged 18–25 years were enrolled in the trial between June 28, 2004, and Dec 21, 200...

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. It has shown encouraging clinical e...

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

Analysis of six randomized phases 3 trials were done to investigate non-inferiority of 3 months versus 6 months of adjuvant chemotherapy. For patients...

Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis

There is a scarcity of data exploring the benefits of adjuvant or neoadjuvant chemotherapy in the treatment of breast cancer in older women. We used d...

Departments

Recent Posts